格卡瑞韦/匹布他韦用于基因1或4型丙型肝炎病毒感染且既往直接抗病毒治疗失败的患者
MAGELLAN-1第2部分是一项随机、开放标签、3期研究,评估无利巴韦林的格卡瑞韦/匹布他韦(G/P,300 mg/120 mg)在既往至少一种NS3/4A蛋白酶和/或NS5A抑制剂治疗失败慢性HCV患者中的疗效与安全性。91例接受治疗者中87例为GT1、4例为GT4,随机接受12周或16周G/P;12周组SVR12为89%(39/44),16周组为91%(43/47),12周组病毒学复发9%(4/44),16周组无复发。
要点
- 12周G/P的SVR12为89%(39/44),16周G/P的SVR12为91%(43/47)。
- 12周G/P病毒学复发9%(4/44),16周G/P无复发。
- 既往仅一类抑制剂(蛋白酶或NS5A)治疗失败不影响SVR12,两类均失败者SVR12率较低。
核心结论
- 16周G/P治疗在既往NS5A抑制剂或NS3蛋白酶抑制剂方案失败的HCV GT1感染患者中达到高SVR12率。
研究设计与样本
- MAGELLAN-1第2部分为随机、开放标签、3期研究,评估无利巴韦林的格卡瑞韦/匹布他韦(G/P;300 mg/120 mg)在慢性HCV且既往至少一种含NS3/4A蛋白酶和/或NS5A抑制剂治疗失败患者中的疗效与安全性。
- 代偿性肝病患者(伴或不伴肝硬化)且HCV基因型为1、4、5或6型,按1:1随机接受12周或16周G/P治疗。
- 共91例患者接受治疗,其中87例为GT1感染、4例为GT4感染。
主要发现
- 12周G/P组SVR12为89%(39/44),16周G/P组SVR12为91%(43/47)。
- 12周G/P组病毒学复发率为9%(4/44),16周G/P组无复发。
- 既往仅一类抑制剂(蛋白酶或NS5A)治疗失败对SVR12无影响,而既往两类抑制剂均治疗失败与较低的SVR12率相关。
- 最常见不良事件为头痛(≥10%患者),无研究者判定与试验药物相关的严重不良事件,也无导致停药的不良事件。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
UNLABELLED: Patients with hepatitis C virus (HCV) who have virological failure (VF) after treatment containing a nonstructural protein 5A (NS5A) inhibitor have limited retreatment options. MAGELLAN-1 Part 2 was a randomized, open-label, phase 3 study to evaluate the efficacy and safety of ribavirin (RBV)-free glecaprevir and pibrentasvir (G/P; 300 mg/120 mg) in patients with chronic HCV and past VF on at least one NS3/4A protease and/or NS5A inhibitor-containing therapy. Patients with compensated liver disease, with or without cirrhosis, and HCV genotype (GT) 1, 4, 5, or 6 were randomized 1:1 to receive 12 or 16 weeks of G/P. The primary endpoint was sustained virological response (SVR) at 12 weeks posttreatment (SVR12). Among 91 patients treated, 87 had GT1 and 4 had GT4 infection. SVR12 was achieved by 89% (39 of 44) and 91% (43 of 47) of patients who received 12 and 16 weeks of G/P, respectively. Virological relapse occurred in 9% (4 of 44) of patients treated with 12 weeks of G/P; there were no relapses with 16 weeks of treatment. Past treatment history with one class of inhibitor (protease or NS5A) had no impact on SVR12, whereas past treatment with both classes of inhibitors was associated with lower SVR12 rate. The most common adverse event (AE) was headache (≥10% of patients), and there were no serious AEs assessed as related to study drugs or AEs leading to discontinuation. CONCLUSION: Sixteen weeks of G/P treatment achieved a high SVR12 rate in patients with HCV GT1 infection and past failure to regimens containing either NS5A inhibitors or NS3 protease inhibitors. (Hepatology 2018;67:1253-1260).
引用
- Poordad F, Pol S, Asatryan A, et al. Glecaprevir/Pibrentasvir in patients with hepatitis C virus genotype 1 or 4 and past direct-acting antiviral treatment failure. Hepatology. 2018. PMID: 29152781. doi:10.1002/hep.29671
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。